The rise of multidrug resistant fungal infections highlights the need to identify and develop novel antifungal agents. Occidiofungin is a nonribosomally synthesized glycolipopeptide that has a unique mechanism of action, disrupting actin-mediated functions and inducing cellular apoptosis. Antifungal activity has been observed in vitro against various fungal species, including multidrug resistant , and in vivo efficacy has been demonstrated in a murine vulvovaginal candidiasis model.
View Article and Find Full Text PDFMutacin 1140 (Mu1140) is a potent antibiotic against Gram-positive bacteria, such as . The antibiotic is produced by the oral bacterium and is a member of the epidermin family of type AI lantibiotics. The antibiotic exerts its inhibitory activity by binding to the cell wall precursor lipid II, blocking cell wall synthesis, and by disrupting bacterial membranes.
View Article and Find Full Text PDFOccidiofungin is a broad-spectrum antifungal compound produced by MS14. It is a cyclic glycol-lipopeptide with a novel beta-amino acid (NAA2) containing a hydroxylated C18 fatty acid chain with a xylose sugar. This study reports a strategy to produce semisynthetic analogs of occidiofungin to further explore the structure activity relationships of this class of compounds.
View Article and Find Full Text PDFAntibiotics (Basel)
August 2022
The identification and development of natural products into novel antimicrobial agents is crucial to combat the rise of multidrug-resistant microorganisms. Clinical fungal isolates have been identified, which have shown resistance to all current clinical antifungals, highlighting a significant need to develop a novel antifungal agent. One of the natural products produced by the bacterium MS14 is the glycolipopeptide occidiofungin.
View Article and Find Full Text PDF